]>
IRCT2014072618596N1 IRCT 2014-08-21 Vice chancellor for Research and Technology, Tabriz University of Medical Science Comparison of visual acuity and macular thickness in patients with macular edema cuased by branch retinal vein occlusion treated with intravitral avastin and intravitral avastin and tissue plasminogen activator BRVO -Branch Retinal Vein Occlusion Comparison of visual acuity and macular thickness in patients with macular edema cuased by branch retinal vein occlusion treated with intravitral avastin and intravitral avastin and tissue plasminogen activator 2014-02-03 anticipated 50 Complete https://irct.ir/trial/16819 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A Retinal vein occlusion. Intervention 1: For the 25 patients Intravitral Avastin and Tissue Plasminogen Activator will be injected. Intervention 2: For the 25 patients Intravitral Avastin will be injected.
public Dr.Sadegi Karim
Nikookari Eye Hospital- Abbasi St.
Tabriz Iran (Islamic Republic of) 5154645395 +98 41 1657 7331 sadegik@tbzmed.ac.irpeymanpourreza1359@gmail.com Tabriz University Of Medical Science scientific Dr.Sadegi Karim
Nikookari Eye Hospital- Abbasi St.
Tabriz Iran (Islamic Republic of) 5154645395 +98 41 1657 7331 sadegik@tbzmed.ac.irpeymanpourreza1359@gmail.com Tabriz Medical University Iran (Islamic Republic of) Inclusion criteria: 1) Having the diagnosis of BRVO. 2) Slit lamp examination: macular edema. 3) Snellen visual acuity: vision worse than 20/40. 4) Optical coherence tomography finding: central macular thickness of 250µm and over on. Exclusion: 1) BRVO associated with vitrous hemorrhage. 2) previous treatment with laser photocoagulation. 3) History of previous vitrectomy. 4)Intraocular pressure more than 21 mmhg. 5) Uncontrolled diabetes. 6) Systemic blood pressure. 7) Uveitis. 8) Any evidence of posterior vitrous detachment. no limit no limit Both H34.8 Retinal vein occlusion_ partial Treatment - Surgery Treatment - Surgery For the 25 patients Intravitral Avastin and Tissue Plasminogen Activator will be injected For the 25 patients Intravitral Avastin will be injected Visual acuity. Timepoint: Before intervention, one month, 3 months, 6 months after intervention. Method of measurement: Snellen chart. Central macular thickness. Timepoint: Before intervention, one month, 3 months, 6 months after intervention. Method of measurement: Optical Coherence tomography. Endophthalmitis. Timepoint: 1, 3 and 6 month after intervention. Method of measurement: clinical. Vice chancellor for Research and Technology, Tabriz University of Medical Science Approved 2014-01-04 Tabriz Uiversity of Mdical Siences Central Department No2, Tabriz University of Medical Sciences, Golgasht st Tabriz Iran (Islamic Republic of)